Evidence map›Paper›PMID 38928397›Full record

ReviewInternational journal of molecular sciences2024

Ocular Changes in Cystic Fibrosis: A Review.

Slawomir Liberski, Filippo Confalonieri, Szczepan Cofta, Goran Petrovski, Jarosław Kocięcki

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Maternal and fetal outcomes associated with CFTR modulator use during pregnancy: a scoping review.European respiratory review : an official journal of the European Respiratory Society · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Slawomir LiberskiDepartment of Ophthalmology, Poznan University of Medical Sciences, A. Szamarzewskiego 84, 61-848 Poznan, Poland.ORCID 0000-0002-6942-2506
Filippo ConfalonieriDepartment of Ophthalmology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy.ORCID 0000-0003-4079-8881
Szczepan CoftaDepartment of Respiratory Medicine, Allergology and Pulmonary Oncology, Poznan University of Medical Sciences, A. Szamarzewskiego 84, 61-848 Poznan, Poland.
Goran PetrovskiCenter for Eye Research and Innovative Diagnostics, Department of Ophthalmology, Institute for Clinical Medicine, University of Oslo, Kirkeveien 166, 0450 Oslo, Norway.ORCID 0000-0003-2905-9252
Jarosław KocięckiDepartment of Ophthalmology, Poznan University of Medical Sciences, A. Szamarzewskiego 84, 61-848 Poznan, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystic fibrosis (CF), also known as mucoviscidosis, is the most common autosomal recessive genetic disease in the Caucasian population, with an estimated frequency of 1:2000-3000 live births. CF results from the mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene localized in the long arm of chromosome 7. The product of CFTR gene expression is CFTR protein, an adenosine triphosphate (ATP)-binding cassette (ABC) transporter that regulates the transport of chloride ions (Cl

Indexed as

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorAnimalsEye DiseasesHumansMutationCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorCFTRcystic fibrosiscystic fibrosis transmembrane conductance regulatoreyemucoviscidosisocular changes

Identifiers

PMID38928397
PMCPMC11203677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.